Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Gains from Investment Securities (2021 - 2024)

Historic Gains from Investment Securities for Kezar Life Sciences (KZR) over the last 4 years, with Q4 2024 value amounting to -$8000.0.

  • Kezar Life Sciences' Gains from Investment Securities changed N/A to -$8000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$16000.0, marking a year-over-year increase of 9830.69%. This contributed to the annual value of -$8000.0 for FY2024, which is 10006.1% down from last year.
  • Per Kezar Life Sciences' latest filing, its Gains from Investment Securities stood at -$8000.0 for Q4 2024.
  • In the past 5 years, Kezar Life Sciences' Gains from Investment Securities ranged from a high of $15.3 million in Q2 2024 and a low of -$1.4 million during Q4 2021
  • Over the past 4 years, Kezar Life Sciences' median Gains from Investment Securities value was $4.9 million (recorded in 2021), while the average stood at $5.6 million.
  • The largest annual percentage gain for Kezar Life Sciences' Gains from Investment Securities in the last 5 years was 2168588.78% (2022), contrasted with its biggest fall of 9316.18% (2022).
  • Kezar Life Sciences' Gains from Investment Securities (Quarter) stood at -$1.4 million in 2021, then skyrocketed by 99.44% to -$8000.0 in 2022, then soared by 166748.89% to $13.3 million in 2023, then tumbled by 100.06% to -$8000.0 in 2024.
  • Its Gains from Investment Securities was -$8000.0 in Q4 2024, compared to $1.7 million in Q3 2024 and $15.3 million in Q2 2024.